Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)

Overview

The Benfotiamine Phase 2 trial (NCT06223360) represents a critical evaluation of a metabolic approach to Alzheimer's disease treatment. Unlike amyloid-targeting immunotherapies that dominate current AD drug development, benfotiamine takes a fundamentally different strategy: targeting the profound cerebral glucose hypometabolism that characterizes Alzheimer's disease pathology. This trial investigates whether improving brain energy metabolism can slow or modify disease progression in patients with early-stage Alzheimer's disease[@benfotiamine_trial][@cerebralglucose2024].

Benfotiamine is a synthetic derivative of thiamine (vitamin B1) that readily crosses the blood-brain barrier and activates thiamine-dependent metabolic pathways critical for neuronal energy production. The scientific rationale stems from decades of research demonstrating that cerebral glucose metabolism is significantly impaired in AD, with reductions detectable decades before clinical symptoms appear. This metabolic deficit affects the very pathways that benfotiamine is designed to support[@thiamine2020][@mitochondrial2024].

Pathway Diagram

Overview

The Benfotiamine Phase 2 trial (NCT06223360) represents a critical evaluation of a metabolic approach to Alzheimer's disease treatment. Unlike amyloid-targeting immunotherapies that dominate current AD drug development, benfotiamine takes a fundamentally different strategy: targeting the profound cerebral glucose hypometabolism that characterizes Alzheimer's disease pathology. This trial investigates whether improving brain energy metabolism can slow or modify disease progression in patients with early-stage Alzheimer's disease[@benfotiamine_trial][@cerebralglucose2024].

Benfotiamine is a synthetic derivative of thiamine (vitamin B1) that readily crosses the blood-brain barrier and activates thiamine-dependent metabolic pathways critical for neuronal energy production. The scientific rationale stems from decades of research demonstrating that cerebral glucose metabolism is significantly impaired in AD, with reductions detectable decades before clinical symptoms appear. This metabolic deficit affects the very pathways that benfotiamine is designed to support[@thiamine2020][@mitochondrial2024].

Pathway Diagram

Trial Details

| Parameter | Details |
|-----------|---------|
| NCT Number | NCT06223360 |
| Phase | Phase 2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Alzheimer's Therapeutic Research Institute |
| Enrollment | 406 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | January 15, 2024 |
| Completion Date | December 31, 2026 |
| Last Updated | February 15, 2026 |

Mechanism of Action

Thiamine-Dependent Enzymes and Brain Energy Metabolism

Benfotiamine serves as a pro-drug that increases thiamine levels in the brain and activates critical thiamine-dependent enzymes. Thiamine is an essential cofactor for three key enzyme complexes in cerebral energy metabolism[@thiamine2020][@pyruvate2019]:

• Catalyzes the conversion of pyruvate to acetyl-CoA
• Links glycolysis to the citric acid cycle (Krebs cycle)
• PDHC activity is reduced by 40-70% in AD brain tissue
• This reduction severely impairs the brain's ability to generate ATP from glucose

• Key rate-limiting enzyme in the citric acid cycle
• Highly vulnerable to oxidative damage in AD
• Activity correlates with cognitive function in AD patients
• Supports mitochondrial energy production and neurotransmitter synthesis

• Central enzyme in the pentose phosphate pathway
• Generates NADPH for antioxidant defense
• Supports lipid synthesis and cellular repair
• Activity is impaired in AD brain

Cerebral Glucose Hypometabolism in AD

The brain relies almost exclusively on glucose for energy, consuming approximately 20% of the body's glucose despite being only 2% of body weight. In Alzheimer's disease, this glucose metabolism is severely impaired[@cerebralglucose2024]:

Patterns of Hypometabolism:

• Posterior cingulate: Often the first region affected
• Temporal and parietal cortex: Progressive decline with disease
• Prefrontal cortex: Associated with executive dysfunction
• Hippocampus: Early involvement in memory impairment

• Reduced ATP production compromises neuronal function
• Inability to maintain ion gradients disrupts neurotransmission
• Impaired cellular repair mechanisms accelerate neurodegeneration
• Vulnerable neurons are unable to withstand pathological insults

Benfotiamine's Multi-Target Effects

Beyond enzyme activation, benfotiamine provides additional benefits[@benfotiamine2018]:

• AGEs form when glucose or its metabolites modify proteins
• AGE accumulation in AD brain contributes to:
• Chronic inflammation (RAGE receptor activation)
• Protein cross-linking and aggregation
• Mitochondrial dysfunction
• Benfotiamine inhibits AGE formation

• Energy-deprived neurons are more vulnerable to Aβ toxicity
• Improving metabolism protects against:
• Oxidative stress
• Calcium dysregulation
• Apoptotic pathways

• Mitochondrial dysfunction triggers inflammatory responses
• Benfotiamine reduces:
• Microglial activation
• Pro-inflammatory cytokine production
• Oxidative stress

Scientific Rationale

The Thiamine Hypothesis in AD

The thiamine hypothesis proposes that thiamine deficiency, either absolute or functional, contributes to the characteristic cerebral hypometabolism of Alzheimer's disease[@tkhypothesis2024]:

Evidence Supporting the Hypothesis:

Why Thiamine Supplementation Has Failed Previously:

• Thiamine itself has poor brain penetration
• Standard doses cannot overcome the magnitude of deficiency
• Short-term supplementation cannot reverse chronic deficits
• Benfotiamine's lipophilic nature overcomes these limitations

Metabolic Therapy vs. Amyloid-Targeted Approaches

The benfotiamine trial represents a fundamentally different therapeutic approach:

| Aspect | Amyloid-Targeted | Metabolic Therapy |
|--------|------------------|-------------------|
| Target | Amyloid plaques | Brain energy metabolism |
| Mechanism | Remove pathological protein | Support cellular function |
| Rationale | Remove upstream trigger | Support downstream function |
| Stage in Disease | Requires early intervention | May work across stages |
| **Combination Potential | Limited | Excellent |

This approach may offer advantages:

• Works through endogenous cellular mechanisms
• Addresses multiple downstream consequences of Aβ
• May be effective even if amyloid removal is incomplete
• Compatible with combination therapy approaches

Preclinical Evidence

Extensive preclinical work supports benfotiamine development:

Animal Studies:

• Benfotiamine improves memory in APP/PS1 transgenic mice
• Reduces amyloid plaque burden by 30-50%
• Decreases neuroinflammation markers
• Preserves hippocampal neuron numbers
• Improves cerebral glucose metabolism on FDG-PET

• Activates PDHC in brain tissue
• Increases ATP production in neurons
• Reduces AGE formation
• Decreases oxidative stress markers

Study Design

Phase 2 Structure

The trial employs a randomized, double-blind, placebo-controlled design:

• Enrollment: 406 participants with early AD
• Randomization: 1:1 ratio to benfotiamine or placebo
• Duration: 52 weeks (1 year)
• Dosing: Oral benfotiamine twice daily

Treatment Arms

Design Rationale

The Phase 2 design reflects learnings from earlier studies:

• Sufficient duration to detect metabolic effects
• Adequate sample size for signal detection
• Early-stage patients most likely to benefit
• Comprehensive biomarker program

Patient Population

Target Population

The trial enrolls patients with early-stage Alzheimer's disease:

• Diagnosis: Probable AD per NIA-AA criteria
• Stage: Mild cognitive impairment due to AD or mild AD dementia
• Age: 50-85 years
• MMSE: 20-26 (mild impairment)

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints

Primary Endpoints

Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

The ADAS-Cog is the gold standard for cognitive assessment in AD trials:

• 11-item version assesses:
• Word recall
• Naming
• Commands
• Construction
• Ideational praxis
• Orientation
• Word recognition
• Remembering instructions
• Higher scores indicate greater impairment
• Clinically meaningful change: 4-6 points

Comprehensive safety assessment:

• Adverse event monitoring
• Laboratory parameters
• Vital signs
• Physical examinations

Secondary Endpoints

• MMSE: Mini-Mental State Examination
• CDR: Clinical Dementia Rating
• RBANS: Repeatable Battery for the Assessment of Neuropsychological Status

• ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
• FAQ: Functional Activities Questionnaire

• FDG-PET: Cerebral glucose metabolism changes
• CSF Biomarkers: Aβ42/40, p-tau, total tau, NfL
• Blood Biomarkers: Inflammatory markers, metabolic parameters

• MRI brain volume measurements
• Connectivity analysis

Biomarker Program

FDG-PET Substudy

The FDG-PET substudy is critical for demonstrating target engagement:

Imaging Protocol:

• Baseline and 52-week FDG-PET
• Regional analysis of glucose metabolism
• Focus on AD-vulnerable regions

• Attenuation of hypometabolism progression
• Improvement in specific regions
• Correlation with clinical outcomes

CSF Biomarker Analysis

Cerebrospinal fluid collection enables:

• Amyloid Markers: Aβ42/40 ratio
• Tau Markers: Total tau, phosphorylated tau
• Neurodegeneration: Neurofilament light chain (NfL)
• Inflammatory Markers: Cytokines, chemokines

Blood Biomarkers

Blood-based markers for monitoring:

• Metabolic Parameters: Glucose, insulin, HbA1c
• Inflammatory Markers: IL-6, TNF-α
• Oxidative Stress: Antioxidant capacity

Clinical Significance

Advancing Metabolic Therapy

The benfotiamine trial represents advancement in several ways:

Potential Impact on AD Treatment

If successful, benfotiamine could:

Comparison to Other Metabolic Approaches

Several metabolic approaches have been investigated in AD:

| Approach | Developer | Status | Mechanism |
|----------|-----------|--------|-----------|
| Benfotiamine | ATRI | Phase 2 | Thiamine activation |
| Pioglitazone | Takeda | Phase 3 (discontinued) | PPARγ agonist |
| Metformin | Various | Phase 3 | AMPK activation |
| ASL0413 | AZ | Phase 1 | Lactate receptor |

The benfotiamine trial is distinguished by its focus on thiamine-dependent enzymes and comprehensive biomarker program.

Safety and Tolerability

Known Safety Profile

Benfotiamine has been used clinically for decades:

• Established Safety: Approved in Japan and other countries for diabetic complications
• Well-Tolerated: Generally mild side effects
• No Significant Interactions: Low drug-drug interaction potential

Expected Adverse Events

Based on previous studies:

• Common: GI upset (nausea, diarrhea)
• Less Common: Headache, dizziness
• Rare: Allergic reactions

Safety Monitoring

The trial includes comprehensive monitoring:

• Regular physical examinations
• Laboratory assessments
• Adverse event documentation
• ECG monitoring (if indicated)

Preceding Clinical Evidence

Earlier Human Studies

Benfotiamine has been studied in cognitive impairment:

MCI Trial (Gibson et al., 2013)[@benfotiamine2013]:

• 12-month randomized controlled trial
• 40 patients with MCI
• Significant improvement in cognitive scores
• Good safety and tolerability

• Improved cognitive scores in type 2 diabetes patients
• Reduced peripheral neuropathy complications
• Established brain penetration

• Preliminary evidence of cognitive benefit
• Improved cerebral metabolism on PET
• Safe and well-tolerated

Dose Selection

The trial dose (300mg twice daily) was selected based on:

• Preclinical studies showing efficacy
• Human studies in other indications
• Brain exposure modeling
• Safety margins

Challenges and Considerations

Potential Limitations

Development Pathway

If Phase 2 is successful:

• Phase 3 trial with larger sample size
• Potential accelerated approval path
• Combination studies with amyloid antibodies

Future Directions

• Early intervention studies
• Prevention trials in at-risk populations
• Combination with disease-modifying agents

Metabolic Therapy in AD: Historical Context

Early Thiamine Research

The exploration of thiamine (vitamin B1) in brain health dates back decades:

1930s-1950s:

• Thiamine discovered and characterized
• Early observations linking thiamine deficiency to neurological symptoms
• Beriberi research established thiamine's role in energy metabolism

• Recognition of thiamine's role in brain function
• Animal studies demonstrating thiamine's impact on cognitive function
• Early post-mortem studies showing thiamine-dependent enzyme deficits in AD brain

• Development of benfotiamine as a brain-penetrant thiamine derivative
• First clinical trials in diabetic neuropathy
• Growing interest in metabolic approaches to neurodegeneration

Evolution of the Thiamine Hypothesis

The thiamine hypothesis has evolved significantly over time:

Original Hypothesis (1970s-1980s):

• Thiamine deficiency as a cause of cognitive decline
• Supplementation as treatment
• Focus on Wernicke-Korsakoff syndrome relationship

• Functional thiamine deficiency in AD (not absolute deficiency)
• Impaired thiamine-dependent enzyme activity
• Targeting upstream metabolic dysfunction
• Benfotiamine as the solution to brain penetration

• Thiamine-dependent enzyme deficits as a consequence of broader metabolic dysfunction
• Role in cerebral glucose hypometabolism
• Potential for combination with other metabolic modulators
• Integration with broader aging and metabolism research

Comparison to Other Metabolic Approaches

Several metabolic approaches have been investigated in AD:

| Approach | Developer | Status | Mechanism | Evidence Level |
|----------|-----------|--------|-----------|-----------------|
| Benfotiamine | ATRI | Phase 2 | Thiamine activation | Preclinical + Phase 1 |
| Pioglitazone | Takeda | Phase 3 (discontinued) | PPARγ agonist | Mixed |
| Metformin | Various | Phase 3 | AMPK activation | Extensive, neutral |
| ASL0413 | AZ | Phase 1 | Lactate receptor | Early |
| Diet ketone supplementation | Various | Research | Ketone metabolism | Preliminary |

The benfotiamine trial is distinguished by its focus on thiamine-dependent enzymes and comprehensive biomarker program.

Scientific Rationale Deep Dive

Thiamine-Dependent Enzymes: Detailed Mechanism

Benfotiamine serves as a pro-drug that increases thiamine levels in the brain and activates critical thiamine-dependent enzymes. Thiamine is an essential cofactor for three key enzyme complexes in cerebral energy metabolism:

Pyruvate Dehydrogenase Complex (PDHC)

Enzyme Function:

• Catalyzes the conversion of pyruvate to acetyl-CoA
• Links glycolysis to the citric acid cycle (Krebs cycle)
• Rate-limiting step in glucose oxidation

• PDHC activity reduced by 40-70% in AD brain tissue
• Post-mortem studies show correlation with cognitive decline
• Activity inversely correlates with neurofibrillary tangle density

• Benfotiamine directly activates PDHC
• Restoring activity could improve neuronal energy production
• May protect against excitotoxicity through improved energy reserve

Alpha-Ketoglutarate Dehydrogenase (α-KGDH)

Enzyme Function:

• Key rate-limiting enzyme in the citric acid cycle
• Catalyzes conversion of α-ketoglutarate to succinyl-CoA
• Generates NADH for ATP production
• Supports neurotransmitter synthesis (GABA, glutamate)

• Highly vulnerable to oxidative damage in AD
• Activity correlates directly with cognitive function
• One of the earliest enzymes affected in AD

• α-KGDH supports mitochondrial energy production
• Restoration may improve neurotransmitter balance
• Protection against oxidative stress through NADPH production

Transketolase (TK)

Enzyme Function:

• Central enzyme in the pentose phosphate pathway
• Generates NADPH for antioxidant defense
• Supports lipid synthesis and cellular repair
• Connects glycolysis to nucleic acid synthesis

• Activity impaired in AD brain
• Reduced NADPH compromises antioxidant capacity
• Impairs cellular repair mechanisms

• TK activation supports antioxidant defense
• May protect against oxidative stress in AD
• Supports cellular repair and membrane maintenance

Cerebral Glucose Hypometabolism: Pathophysiology

The brain relies almost exclusively on glucose for energy, consuming approximately 20% of the body's glucose despite being only 2% of body weight. In Alzheimer's disease, this glucose metabolism is severely impaired:

Regional Patterns of Hypometabolism

Posterior Cingulate Cortex:

• Often the first region affected
• Critical for memory encoding and retrieval
• Hypometabolism detectable decades before diagnosis
• Strong correlation with amyloid burden

• Progressive decline with disease
• Associated with language and spatial function
• Correlates with clinical severity

• Associated with executive dysfunction
• Affected in later disease stages
• Contributes to behavioral symptoms

• Early involvement in memory impairment
• Critical for memory consolidation
• Volume loss accompanies hypometabolism

Mechanisms of Hypometabolism

Amyloid-Induced Dysfunction:

• Aβ oligomers directly impair glucose transporters
• Synaptic dysfunction reduces glucose demand
• Mitochondrial dysfunction impairs utilization

• Neurofibrillary tangles correlate with hypometabolism
• Neuronal loss reduces metabolic demand
• Axonal dysfunction impairs glucose distribution

• Cerebral amyloid angiopathy affects blood flow
• Capillary dysfunction impairs delivery
• Neurovascular unit dysfunction

Consequences of Hypometabolism

• Reduced ATP production compromises neuronal function
• Inability to maintain ion gradients disrupts neurotransmission
• Impaired cellular repair mechanisms accelerate neurodegeneration
• Vulnerable neurons are unable to withstand pathological insults

Benfotiamine's Multi-Target Effects

Beyond enzyme activation, benfotiamine provides additional benefits:

Advanced Glycation End Products (AGEs) Reduction

AGEs form when glucose or its metabolites modify proteins, lipids, or nucleic acids. In AD:

AGE Formation Pathways:

• Non-enzymatic glycation (Maillard reaction)
• Oxidative stress-driven formation
• Metabolism-driven modification

• Contributes to chronic inflammation through RAGE receptor activation
• Promotes protein cross-linking and aggregation
• Directly damages mitochondria
• Accelerates amyloid and tau pathology

• Inhibits AGE formation
• Reduces RAGE activation
• Decreases inflammatory signaling

Amyloid-Beta Toxicity Mitigation

Energy-deprived neurons are more vulnerable to Aβ toxicity:

Mechanisms of Protection:

• Improved ATP production supports cellular defense
• Reduced oxidative stress diminishes vulnerability
• Enhanced calcium regulation prevents toxicity
• Maintained cellular repair capacity

• Benfotiamine improves survival of neurons exposed to Aβ
• Reduces markers of oxidative stress
• Preserves synaptic function

Neuroinflammation Modulation

Mitochondrial dysfunction triggers inflammatory responses:

Inflammatory Cascade:

• Damaged mitochondria release DAMPs
• Microglial activation
• Pro-inflammatory cytokine production
• Chronic neuroinflammation

• Reduces microglial activation
• Decreases pro-inflammatory cytokine production
• Supports anti-inflammatory pathways
• Reduces oxidative stress

Clinical Trial Design Deep Dive

Phase 2 Structure

The trial employs a randomized, double-blind, placebo-controlled design:

Design Rationale

• Randomization: Ensures balanced groups for valid comparison
• Double-blind: Prevents bias in outcome assessment
• Placebo-controlled: Provides clear evidence of treatment effect
• Phase 2: Appropriate for signal detection before larger Phase 3 investment

Key Design Features

Enrollment: 406 participants with early AD

• Sufficient for detecting moderate effect sizes
• Realistic for single-site trial
• Adequate for regulatory discussion

• Equal probability of assignment
• Standard approach for Phase 2
• Enables straightforward statistical analysis

• Sufficient duration to detect metabolic effects
• Matches standard AD trial durations
• Allows for biomarker assessment

• 300mg dose selected based on preclinical and clinical data
• Twice-daily to maintain stable blood levels
• Established as well-tolerated in previous studies

Patient Population Deep Dive

Target Population

The trial enrolls patients with early-stage Alzheimer's disease:

Diagnosis: Probable AD per NIA-AA criteria

• Core clinical criteria for AD
• Excludes other causes of dementia
• Ensures homogeneous population

• Early stage most likely to benefit
• Can complete all study procedures
• Clear baseline for measuring progression

• Appropriate age range for typical AD
• Excludes very early-onset (rare) and very late-onset (comorbidities)

• Ensures ability to complete assessments
• Excludes severe dementia (too advanced)
• Excludes very mild (floor/ceiling effects)

Inclusion/Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints Deep Dive

Primary Endpoints

Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)

The ADAS-Cog is the gold standard for cognitive assessment in AD trials:

11-item version assesses:

• Word recall: Immediate and delayed recall of 10 words
• Naming: Name objects and fingers
• Commands: Follow spoken commands
• Construction: Copy two overlapping pentagons
• Ideational praxia: Mail a letter
• Orientation: Date, time, place
• Word recognition: Identify learned words
• Remembering instructions: Follow spoken instructions
• Spoken language: Describe picture
• Word finding difficulty: Name items
• Comprehension: Respond to questions

• Higher scores indicate greater impairment
• Score range: 0-70 (typical)
• Clinically meaningful change: 4-6 points
• Minimum detectable change: ~2 points

Comprehensive safety assessment:

• Adverse event monitoring
• Laboratory parameters
• Vital signs
• Physical examinations

Secondary Endpoints

• MMSE: Mini-Mental State Examination
• CDR: Clinical Dementia Rating
• RBANS: Repeatable Battery for the Assessment of Neuropsychological Status

• ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
• FAQ: Functional Activities Questionnaire

• FDG-PET: Cerebral glucose metabolism changes
• CSF Biomarkers: Aβ42/40, p-tau, total tau, NfL
• Blood Biomarkers: Inflammatory markers, metabolic parameters

• MRI brain volume measurements
• Connectivity analysis

Biomarker Program Deep Dive

FDG-PET Substudy

The FDG-PET substudy is critical for demonstrating target engagement:

Imaging Protocol

• Baseline and 52-week FDG-PET
• Regional analysis of glucose metabolism
• Focus on AD-vulnerable regions

Expected Findings

• Attenuation of hypometabolism progression
• Improvement in specific regions
• Correlation with clinical outcomes

Scientific Rationale

FDG-PET directly measures the mechanism of benfotiamine action:

• Restoration of thiamine-dependent enzyme activity
• Improved cerebral glucose metabolism
• Correlation with cognitive outcomes

CSF Biomarker Analysis

Cerebrospinal fluid collections enable:

Amyloid Markers

• Aβ42/40 ratio: Confirms amyloid pathology
• Changes with treatment may indicate downstream effects

Tau Markers

• Total tau: Marker of neuronal damage
• Phospho-tau: Marker of tau pathology

Neurodegeneration Markers

• Neurofilament light chain (NfL): Marker of axonal injury
• May be reduced with neuroprotection

Inflammatory Markers

• Cytokines, chemokines: Measure neuroinflammation
• May be reduced with benfotiamine's anti-inflammatory effects

Blood Biomarkers

Blood-based markers for monitoring:

Metabolic Parameters

• Glucose, insulin, HbA1c: Metabolic status
• Thiamine levels: Compliance marker

Inflammatory Markers

• IL-6, TNF-α: Pro-inflammatory cytokines
• May be reduced with treatment

Oxidative Stress

• Antioxidant capacity: Measure of oxidative stress
• May improve with treatment

Safety and Tolerability Deep Dive

Known Safety Profile

Benfotiamine has been used clinically for decades:

Established Safety:

• Approved in Japan and other countries for diabetic complications
• Decades of clinical use
• Well-characterized safety profile

• Generally mild side effects
• Low discontinuation rates
• No significant organ toxicity

• Low drug-drug interaction potential
• Non-CYP metabolism
• Safe in hepatic impairment

Expected Adverse Events

Based on previous studies:

Common (≥1%):

• GI upset (nausea, diarrhea)
• Usually mild and transient
• May improve with food

• Headache
• Dizziness
• Generally not treatment-limiting

• Allergic reactions
• Discontinue if occurs

Safety Monitoring

The trial includes comprehensive monitoring:

• Regular physical examinations
• Laboratory assessments
• Adverse event documentation
• ECG monitoring (if indicated)
• MRI for safety (if indicated)

Comparison to Other AD Treatments

| Treatment | Class | Key Safety Concerns | Serious AE Rate |
|-----------|-------|-------------------|-----------------|
| Benfotiamine | Metabolic | GI upset | Low |
| Lecanemab | Anti-amyloid | ARIA (brain edema) | ~12% |
| Donanemab | Anti-amyloid | ARIA (brain edema) | ~24% |
| Donepezil | Cholinesterase inhibitor | GI, bradycardia | Low |
| Memantine | NMDA antagonist | Dizziness, headache | Low |

Related Pages

Clinical Trials

• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Lecanemab CLARITY-AD](/clinical-trials/lecanemab-clarity-ad)
• [Remternetug TRAILRUNNER-ALZ 3](/clinical-trials/nct06653153)

Mechanisms

• [Cerebral Glucose Hypometabolism](/mechanisms/cerebral-glucose-hypometabolism)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Metabolic Dysfunction in Alzheimer's](/mechanisms/metabolic-dysfunction-alzheimers)
• [Neuroinflammation](/mechanisms/neuroinflammation)

Proteins and Genes

• [APP](/proteins/app)
• [Tau Protein](/proteins/tau)
• [TNF](/proteins/tnf)

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
• [Type 3 Diabetes Hypothesis](/diseases/type-3-diabetes-hypothesis)

External Links

• [ClinicalTrials.gov Record - NCT06223360](https://clinicaltrials.gov/study/NCT06223360)
• [Alzheimer's Therapeutic Research Institute](https://www.ATRI-LA.org)
• [Alzheimer's Association Research](https://www.alz.org/research)

References

See Also

Related Hypotheses:

• [LRP1-Dependent Tau Uptake Disruption](/hypotheses/h-4dd0d19b)
• [TREM2-mediated microglial tau clearance enhancement](/hypotheses/h-b234254c)
• [Extracellular Vesicle Biogenesis Modulation](/hypotheses/h-55ef81c5)
• [VCP-Mediated Autophagy Enhancement](/hypotheses/h-18a0fcc6)
• [HSP90-Tau Disaggregation Complex Enhancement](/hypotheses/h-0f00fd75)

• [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
• [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)

Pathway Diagram

The following diagram shows the key molecular relationships involving Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360) discovered through SciDEX knowledge graph analysis: